Person:
GÜL, AYŞE ZEHRA

Profile Picture
Status
Kurumdan Ayrılmıştır.
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
AYŞE ZEHRA
Last Name
GÜL
Name
Email Address
Birth Date

Filters

2021 - 20232
Reset filters

Settings

Rights: info:eu-repo/semantics/openAccess ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    Mass spectrometry-based untargeted metabolomics study of non-obese individuals with non-alcoholic fatty liver disease
    (2023-06-01) Demirel M.; Köktaşoğlu F.; Özkan E.; Dulun Ağaç H.; Gül A. Z.; Sharifov R.; Sarıkaya U.; Başaranoğlu M.; Selek Ş.; DEMİREL, METİN; KÖKTAŞOĞLU, FATMANUR; DULUN AĞAÇ, HALİME; GÜL, AYŞE ZEHRA; SARIKAYA, UFUK; BAŞARANOĞLU, METİN; SELEK, ŞAHABETTİN
    Objectives: Non-alcoholic fatty liver disease (NAFLD) is a disease characterized by the accumulation of excessive fat in the liver, which can lead to fibrosis and has an increasing prevalence. NAFLD requires non-invasive diagnostic biomarkers. While typically observed in overweight individuals, it can also occur in non-obese/non-overweight individuals. Comparative studies on non-obese NAFLD patients are scarce. This study aimed to conduct a using liquid chromatography-high resolution mass spectrometry (LC-MS/MS)-based metabolic profiling of non-obese NAFLD patients and healthy controls. Materials and methods: The patient group consisted of 27 individuals with NAFLD, while the healthy control group included 39 individuals. Both groups were between 18 and 40 years old, had a BMI of less than 25 and had alcohol consumption less than 20 g/week for men and 10 g/week for women. Serum samples were collected and analyzed using LC-MS/MS. The data were analyzed using the TidyMass and MetaboAnalyst. Results: The LC-MS/MS analyses detected significant changes in D-amino acid metabolism, vitamin B6 metabolism, apoptosis, mTOR signaling pathway, lysine degradation, and phenylalanine metabolism pathways in non-obese NAFLD patients. Significant changes were also observed in the metabolites D-pantothenic acid, hypoxanthine, citric acid, citramalic acid, L-phenylalanine, glutamine, and histamine-trifluoromethyl-toluidide, β-hydroxymyristic acid, DL-Lactic acid, and 3-methyl-2-oxopentanoic. Overall, the study provides valuable insights into the metabolic changes associated with non-obese NAFLD patients and can contribute to the development of non-invasive diagnostic biomarkers for NAFLD.
  • No Thumbnail Available
    PublicationMetadata only
    The Importance of Postpartum Kleihauer-Betke Test in Low Risk Rh-Incompatible Pregnant Population
    (2021-04-01T00:00:00Z) Bilgili, Ümmühan Zeynep; Gül, Ayşe Zehra; Kütük, Mehmet Serdar; GÜL, AYŞE ZEHRA; KÜTÜK, MEHMET SERDAR
    Introduction: Prevalence of Rh disease is estimated to be 276 per 100,000 live births, which is significant considering its relationship with conditions like fetal anemia, hydrops fetalis, fetal death and recurrent fetal demises in future pregnancies. In order to prevent these, anti-D immunoglobulin should be given after inciting events, in a dose sufficient. In Turkey and some other countries, anti-D dose is given on -one shot fits for all- principle. Here, we challenge the conventional wisdom and evaluate the amount of fetomaternal hemorrhage (FMH) and adjusted the dose of anti-D accordingly. Method: In our study, Rh incompatible women who gave birth between October 2020 and March 2021 were included. FMH was determined by the Kleihauer-Betke test in the blood sample taken from the mothers after delivery. Blood smears were fixed with ethyl alcohol and incubated in citric acid buffer solution. In acid medium, HbF becomes resistant to elution, while other types are removed from erythrocytes. The smears are then taken under a microscope to examine the percentage of cells containing fetal hemoglobin. We used Oski-Naiman method to count fetal cells present, then estimated FMH using Mollison-s formula. Clinical data were available at hospital-s digital system. Results: Seventy patients got tested during study period. Twenty-five (39.6%) of cases had more than 4 mL of FMH. Among them, one (1.6%) case was found to have more than 30 mL of FMH, and was given an additional dose. This case had no obstetrical risk factor such as antepartum bleeding, preeclampsia, or manual removal of placenta. The rate of smoking was significantly higher in cases with more than 4 mL of FMH (p=0.001). There were no other variables differed significantly in women having more than 4 mL of FMH. Conclusion: FMH requiring more than 300 mcg of anti-D is significantly high in low-risk pregnant women in Turkey. Implementation of quantitative FMH testing with Kleihauer-Betke or flow cytometry test is necessary. Key words: Fetomaternal hemorrhage, Rh incompatibility